ELMMB logo
Facebook logo Twitter logo
Menu

4.2.2 Antipsychotic depot injections

4.2.2 Antipsychotic depot injections 

Can be used for maintenance when compliance is a problem. 
AMBER          Flupentixol decanoate
                       injection 20mg/ml, 1mL, 2mL 
                       concentrate injection 100mg/ml, 0.5mL, 1mL  
AMBER          Fluphenazine decanoate
                       injection 25mg/ml, 0.5ml amp, 
AMBER          Haloperidol decanoate injection 100mg/mL
AMBER          Pipotiazine palmitate injection 50mg/ml  
AMBER          Zuclopenthixol decanoate injection 200mg/ml, 500mg/ml 
 
Risperdal Consta®  
Risperdal Consta® restricted use – request from doctor must be sent to chief pharmacist and medical director of Lancashire Care Trust
before authorised to prescribe
RED                     Risperidone (Risperdal Consta®) injection 
                            25mg, 37.5mg. 50mg
 
Abilify Maintena®, Xeplion®
Aripiprazole prolonged-release (PR) suspension for injection and Paliperidone palmitate (PR) suspension for injection are 
recommended as treatment options in the maintenance treatment of schizophrenia in adult patients stabilised with oral
aripiprazole where both of the following criteria are met;
 
          >     where treatment is in line with the recommendations within NICE CG178 for the use of depot or long-acting injectable
                 antipsychotic medication and
          >     where treatment is in line with the Lancashire Care Guidance for Prescribing Second Generation Long Acting 
                 Antipsychotic Injections  
 
RED        Aripiprazole (Abilify Maintena®) prolonged release suspension for injection, 400mg powder and solvent
RED        *Paliperidone (Xeplion®) prolonged release suspension for injection, 50mg, 75mg,100mg,150mg  
 
 Paliperidone palmitate prolonged release suspension for injection (six monthly)
 Paliperidone palmitate 6-monthly injection is recommended as a treatment option for the maintenance treatment of 
 schizophrenia in adult patients who are clinically stable on 1-monthly or 3-monthly paliperidone palmitate injectable products:
      >  where treatment is in line with the recommendations within NICE CG178 for the use of depot or long-acting injectable
          antipsychotic medications, and
      >  where treatment is in line with the Lancashire Care Guidance for Prescribing Second Generation Long Acting Antipsychotic
          injections
 RED Paliperidone palmitate prolonged release suspension for injection (six monthly) (Byannli)
 
 
*MHRA Drug Safety Alert - Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery 
 



  






All material in this section is aimed at health care professionals, but is information currently held in the public domain, members of the
public seeking advice on medicine-related matters are advised to speak with their GP, pharmacist, nurse or contact NHS111 Service 
    Email: info.elmmb@nhs.net
 
 Copyright© 2016 East Lancashire Medicines Management Board. 
 All rights reserved.  Disclaimer/Terms and conditions